seed
Stage
2021
Founded
1
Investors
About
ParcelBio develops APEXm™, a proprietary mRNA platform (Amplified and Prolonged Expression mRNA) that increases protein expression potency and durability to enable durable mRNA medicines, including in vivo CAR-T, oncology applications, autoimmune disease therapies, and therapeutic protein delivery.
Explore ParcelBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.